Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company, announced the acceptance of multiple abstracts at the 13th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, from May 4-7. They will present significant findings including:

• Route of Administration Preferences for Hereditary Angioedema treatment, presented on May 5.
• Rationale for the Short-term Prophylaxis Regimen with Sebetralstat on May 6.
• HAE Patients' Decision to carry on-demand treatment, also on May 6.

KalVista is developing sebetralstat as an oral therapy for HAE attacks and is currently enrolling in the Phase 3 KONFIDENT clinical trial, aiming to enhance treatment options for patients.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company, will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 11:00 a.m. ET. A live webcast will be available on their website, along with an audio archive accessible for 30 days post-event.

KalVista is focused on the development of oral, small molecule protease inhibitors for unmet medical needs, including sebetralstat, which is in the Phase 3 KONFIDENT clinical trial for HAE attacks. They are also advancing an oral Factor XIIa inhibitor program aimed at enhancing treatment options for HAE and other conditions.

KalVista Pharmaceuticals (KALV) reported significant operational progress, achieving over 50% enrollment in the pivotal phase 3 KONFIDENT trial for sebetralstat. The company completed a $58 million financing, ensuring funding into 2025, while publishing phase 2 trial results in The Lancet. Q3 financial results showed no revenue and a net loss of $21.3 million, an improvement from $22.5 million year-over-year. R&D expenses increased to $20.1 million, reflecting ongoing clinical trials. KalVista remains focused on addressing hereditary angioedema treatment needs and plans to utilize new funding for trials and general corporate purposes.

KalVista Pharmaceuticals presented five posters at the 2023 AAAAI Annual Meeting in San Antonio, Texas, showcasing key findings related to sebetralstat, an oral treatment for Hereditary Angioedema (HAE). The research indicates that orally disintegrating tablets display similar pharmacokinetics to existing film-coated tablets, which supports potential lifecycle extensions in the US and EU. Data also illustrate the treatment burden of injectable therapies, with an emphasis on the advantages of sebetralstat. Notably, Phase 2 trial results show that early treatment can significantly lower attack severity and cumulative symptom burden compared to placebo.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the acceptance of multiple abstracts for the 2023 Annual Scientific Meeting of the American Academy of Allergy, Asthma & Immunology in San Antonio, Texas, from February 24-27. Results from studies will be presented on February 26 from 9:45-10:45 a.m. CST. Key presentations include:

• Treatment with Sebetralstat for hereditary angioedema.
• Comparative bioavailability of Sebetralstat.
• Anxiety related to on-demand treatment for hereditary angioedema.
• Patient perspectives on early treatment for hereditary angioedema.
• Adverse drug reactions from parenteral treatments for hereditary angioedema.

KalVista focuses on oral protease inhibitors for unmet medical needs.